Amalgamated Financial’s BioCryst Pharmaceuticals BCRX Stock Holding History

Amalgamated Financial’s Portfolio BCRX Stock Details BCRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q1	$375K	Buy	+23,092	New	+$370K	﹤0.01%	1642

Other funds holding BCRX

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

PAMS

Pictet Asset Management (Switzerland) Geneva 73, Switzerland $84.3B AUM 26.5% 1-Year Est. Return

Fisher Asset Management Camas, Washington $336B AUM 34.66% 1-Year Est. Return

RP Management New York $139M AUM 37.98% 1-Year Est. Return

Victory Capital Management San Antonio, Texas $156B AUM 27.51% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Amalgamated Financial's BCRX Position: Q1 2022 in Review

Amalgamated Financial opened a new position in BioCryst Pharmaceuticals (BCRX) in Q1 2022: 23,092 shares worth $375K. The stake represents ﹤0.01% of the portfolio and ranks #1642 among its holdings.

233 funds tracked by Wall St. Rank hold BCRX as of Q1 2022.

Amalgamated Financial held 23,092 shares of BioCryst Pharmaceuticals worth $375K as of Q1 2022.
BioCryst Pharmaceuticals was a new Amalgamated Financial position in Q1 2022.
BioCryst Pharmaceuticals made up ﹤0.01% of Amalgamated Financial's portfolio in Q1 2022, its #1642 holding.
233 funds tracked by Wall St. Rank held BioCryst Pharmaceuticals as of Q1 2022.

Based on Amalgamated Financial's 13F filing for Q1 2022, filed 16 May 2022.